VYNE Therapeutics Inc. filed its 10-K on Mar 14, 2023 for the period ending Dec 31, 2022. In this report its auditor, Baker Tilly, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.838 USD | -1.80% | +4.34% | +21.80% |
May. 09 | Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q1 Revenue $98,000 | MT |
May. 09 | VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.80% | 40.75M | |
+31.37% | 588B | |
-2.80% | 364B | |
+20.52% | 326B | |
+5.55% | 285B | |
+14.83% | 239B | |
+9.93% | 210B | |
-6.95% | 200B | |
+10.84% | 167B | |
+0.16% | 161B |
- Stock Market
- Equities
- VYNE Stock
- News VYNE Therapeutics Inc.
- VYNE Therapeutics Inc. Auditor Raises 'Going Concern' Doubt